0.6653 USD
+0 (+0.47%)
0.665 USD
0 (-0.05%)
ChartMill assigns a Buy % Consensus number of 83% to XLO. The Buy consensus is the weighted average rating of the current analysts ratings.
XLO was analyzed by 6 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about XLO.
In the previous month the buy percentage consensus was at a similar level.
XLO was analyzed by 6 analysts. More opinions would make the average more meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-06 | Leerink Partners | Initiate | Outperform |
| 2024-11-08 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-05-30 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Reiterate | Buy |
| 2023-01-27 | Morgan Stanley | Maintains | Overweight |
| 2022-12-21 | Chardan Capital | Initiate | Buy |
| 2022-11-10 | Raymond James | Maintains | Outperform |
| 2022-08-10 | Morgan Stanley | Maintains | Overweight |
| 2022-01-10 | HC Wainwright & Co. | Initiate | Buy |
| 2021-11-16 | Cowen & Co. | Initiate | Outperform |
| 2021-11-16 | Raymond James | Initiate | Outperform |
| 2021-11-16 | Morgan Stanley | Initiate | Overweight |
XILIO THERAPEUTICS INC / XLO FAQ
What is the consensus rating for XLO stock?
The consensus rating for XILIO THERAPEUTICS INC (XLO) is 83.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.